Use of dipyrone during pregnancy and risk of congenital anomalies: a systematic review
Authors:
- Karine Duarte CurvelloKCKarine Duarte Curvello
- Helana Ortiz GarciaHGHelana Ortiz Garcia
- Tatiana da Silva SempéTSTatiana da Silva Sempé
- Raimunda Alyne Maciel Feitosa da SilvaRSRaimunda Alyne Maciel Feitosa da Silva
- Luana Giongo PedrottiLPLuana Giongo Pedrotti
- Fernanda Sales Luiz ViannaFVFernanda Sales Luiz Vianna
- Tatiane da Silva Dal PizzolTPTatiane da Silva Dal Pizzol
- 24 October 2024
- journal article
- review article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 81 (1) , 35-44
Abstract
Purpose This study aimed to summarize the evidence on the teratogenic effects of dipyrone used during pregnancy. Methods Databases (MEDLINE, EMBASE, Cochrane Library, CINAHL, Web of Science, Lilacs, SciELO, SCOPUS, OasisBR, and OpenGray) were reviewed until September 2023. We included studies that compared pregnant women who used dipyrone during any gestational period with those who used other analgesics or did not use any analgesics during the same gestational period. The outcome assessed was the presence of any congenital anomaly. Two reviewers independently conducted the review process, and a third reviewer resolved any disagreements. The risk of bias was assessed using the Joanna Briggs Institute tool for observational studies. The reviewed data synthesis is presented in narrative form. Results The search retrieved 2045 results, of which seven studies were included in the review, four were case‒control studies, and three were cohort studies involving 153,562 participants. The congenital anomalies evaluated varied across studies, with unspecified congenital anomalies predominating. Five of seven studies found no association between dipyrone and congenital anomalies. In a case‒control study, a positive association was found between dipyrone use and isolated congenital cataracts compared to two control groups; in another study, a positive association for unspecified congenital anomalies was observed in only one of the two control groups analyzed. In all studies, a high risk of bias was identified, especially regarding measuring the exposure, outcome, and assessment of confounding factors. Conclusion There is not enough evidence to define the risk of congenital anomalies associated with dipyrone use during pregnancy. Registration CRD 42022333041.Keywords
This publication has 28 references indexed in Scilit:
- Acetaminophen Use During Pregnancy and Children’s Risk of Autism, ADHD, and Intellectual DisabilityJAMA, 2024
- Emergency Care Utilization Among Pregnant Medicaid Recipients in North Carolina: An Analysis Using Linked Claims and Birth RecordsMaternal and Child Health Journal, 2019
- Emergency department use during pregnancy: a prospective observational study in a single center institutionArchives of Gynecology and Obstetrics, 2018
- Metamizole use during first trimester—A prospective observational cohort study on pregnancy outcomePharmacoepidemiology and Drug Safety, 2017
- Prenatal acetaminophen use and outcomes in childrenAmerican Journal of Obstetrics and Gynecology, 2017
- Non-prescription (OTC) oral analgesics for acute pain - an overview of Cochrane reviewsCochrane Database of Systematic Reviews, 2015
- Dipyrone use during pregnancy and adverse perinatal eventsArchives of Gynecology and Obstetrics, 2008
- Population‐based case‐control study of isolated congenital cataractBirth Defects Research Part A: Clinical and Molecular Teratology, 2005
- Prenatal Constriction of the Fetal Ductus Arteriosus - Related to Maternal Pain Medication?Zeitschrift für Geburtshilfe und Neonatologie, 2005
- Metamizol (dipyrone, optalgin) in pregnancy, is it safe? A prospective comparative studyEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 2005